文献速递生殖医学

超声诊断卵巢子宫内膜瘤行体外受精女性中,两种两个月GnRH激动剂预处理联合或不联合芳香化酶抑制剂的比较

A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF.
PubMed 文献 · Reprod Biomed Online · 2018-12-22

回顾性两中心队列研究纳入126名21-39岁、既往IVF周期失败且有超声证据的子宫内膜瘤女性,非随机接受3.75 mg肌注depo-leuprolide单用或联合口服来曲唑5 mg/日共60天预处理后行新鲜IVF周期。来曲唑组临床妊娠率50% vs 22%(P=0.003),活产率40% vs 17%(P=0.008),作者认为联合方案结局更优。

要点

  • 来曲唑联合组临床妊娠率50% vs 单用组22%(P=0.003)。
  • 来曲唑联合组活产率40% vs 单用组17%(P=0.008)。
  • 来曲唑联合组促性腺激素用量更低、成熟卵母细胞更多。

核心结论

  • 作者认为,对于有子宫内膜瘤的女性,depo-leuprolide acetate每月一次共60天联合每日来曲唑在IVF中的临床结局优于单用depo-leuprolide acetate。

研究设计与样本

  • 回顾性两中心队列研究,纳入126名21-39岁、既往IVF周期及所有后续胚胎移植失败且有超声证据的子宫内膜瘤女性。
  • 女性非随机分配至单用3.75 mg肌注depo-leuprolide或联合口服来曲唑5 mg/日共60天,随后行新鲜IVF周期。
  • 主要结局指标包括临床妊娠率和妊娠24周后的持续妊娠率。

主要发现

  • 治疗前,两组窦卵泡计数(AFC)、基础血清FSH和子宫内膜瘤直径无差异。
  • 治疗后,来曲唑组与非来曲唑组AFC分别为10.3 ± 2.0 vs 6.4 ± 2.5(P = 0.0001),子宫内膜瘤平均最大直径分别为1.8 ± 0.4 cm vs 3.2 ± 0.8 cm(P = 0.0001)。
  • IVF时,来曲唑组促性腺激素用量显著更低(2079 ± 1119 vs 3716 ± 1314;P = 0.0001),获成熟卵母细胞数更多(9.1 ± 2.4 vs 4.0 ± 1.7;P = 0.0001),双原核胚胎数和囊胚数亦更多。
  • 来曲唑组临床妊娠率显著更高(50% vs 22%,P = 0.003),活产率亦显著更高(40% vs 17%,P = 0.008)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does the addition of an aromatase inhibitor improve IVF outcomes in women with endometriomas when pretreating them with gonadotrophin-releasing hormone agonists? DESIGN: Retrospective two-centre cohort study involving 126 women aged 21-39 years who failed a previous IVF cycle and all subsequent embryo transfers and had sonographic evidence of endometriomas. Women were non-randomly assigned to either 3.75 mg intramuscular depo-leuprolide treatment alone or in combination with 5 mg of oral letrozole daily for 60 days prior to undergoing a fresh IVF cycle. Main outcome measures included clinical pregnancy rate and ongoing pregnancy rate after 24 weeks' gestation. RESULTS: Prior to treatment, antral follicle count (AFC), basal serum FSH and endometrioma diameter did not differ between groups. After treatment, AFC differed between letrozole and non-letrozole-treated groups (10.3 ± 2.0 versus 6.4 ± 2.5; P = 0.0001), as did mean endometrioma maximum diameter (1.8 ± 0.4 cm versus 3.2 ± 0.8 cm; P = 0.0001). At IVF, the gonadotrophin dose used was significantly lower in letrozole-treated subjects (2079 ± 1119 versus 3716 ± 1314; P = 0.0001), the number of mature oocytes collected was greater (9.1 ± 2.4 versus 4.0 ± 1.7; P = 0.0001), as were the number of two-pronuclear embryos and number of blastocysts. The clinical pregnancy rate was significantly higher in the letrozole-treated group (50% versus 22%, P = 0.003), as was the live birth rate (40% versus 17%, P = 0.008). CONCLUSIONS: The combination of depo-leuprolide acetate monthly for 60 days combined with daily letrozole has better clinical outcomes at IVF in women with endometriomas than depo-leuprolide acetate treatment alone.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Cantor A, Tannus S, Son WY, et al. A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF. Reprod Biomed Online. 2018. PMID: 30935663. doi:10.1016/j.rbmo.2018.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。